Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction (CHIP in STEMI)

22 mei 2026 bijgewerkt door: Medical University Innsbruck

Clonal Hematopoiesis of Indeterminate Potential (CHIP) refers to the age-related expansion of hematopoietic stem cell clones carrying somatic mutations in leukemia-associated driver genes (e.g., DNMT3A, TET2, ASXL1) in the absence of a hematological malignancy. CHIP has been identified as an independent cardiovascular risk factor associated with increased rates of myocardial infarction, stroke, and cardiovascular mortality, likely mediated through enhanced inflammatory signaling in mutant macrophages and monocytes.

ST-elevation myocardial infarction (STEMI) is a life-threatening emergency requiring immediate reperfusion by primary percutaneous coronary intervention (PCI). Despite successful reperfusion, adverse cardiac remodeling and heart failure may occur depending on myocardial injury severity, microvascular obstruction (MVO), and intramyocardial hemorrhage (IMH) - phenomena substantially driven by ischemia-reperfusion injury and the inflammatory response.

The CHIP in STEMI study is a prospective, observational, single-center cohort study at the Medical University of Innsbruck investigating whether CHIP - detected by targeted next-generation sequencing - is associated with greater infarct severity and worse cardiac outcomes in STEMI patients undergoing primary PCI. The primary endpoint is the presence of MVO and/or IMH on cardiac MRI (CMR) at 5±2 days post-PCI. Secondary endpoints include infarct size, left and right ventricular function, major adverse cardiovascular events (MACE), and immune cell transcriptome profiling by single-cell RNA sequencing.

350 patients (18-75 years, minimum 90 female) will be enrolled over 36 months and followed for 4 years (2026-2030).

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Background and Rationale:

CHIP mutations - particularly in TET2 and DNMT3A - promote a pro-inflammatory state in hematopoietic cells. Preclinical data demonstrate that TET2-deficient macrophages exhibit exaggerated NLRP3 inflammasome activation and IL-1β secretion, while DNMT3A mutations impair immune resolution after myocardial ischemia. This enhanced inflammatory signaling may worsen myocardial ischemia-reperfusion injury (IRI), thereby increasing MVO, IMH, and infarct size in CHIP carriers presenting with STEMI.

Study Design:

Prospective, observational, single-center cohort study. No intervention beyond standard of care.

Study Population:

350 patients aged 18-75 years with STEMI undergoing primary PCI at the University Clinic of Internal Medicine III - Cardiology and Angiology, Medical University of Innsbruck. A minimum of 90 female participants will be enrolled.

Key Inclusion Criteria:

  • Age 18-75 years
  • STEMI with symptom onset ≤12 hours before PCI
  • Successful primary PCI of culprit lesion
  • Written informed consent

Key Exclusion Criteria:

  • Prior myocardial infarction or known cardiomyopathy
  • Known hematological malignancy
  • Contraindication to CMR (pacemaker, severe claustrophobia, eGFR <30 mL/min/1.73m²)
  • Cardiogenic shock requiring mechanical circulatory support
  • Life expectancy <12 months due to non-cardiac cause
  • Pregnancy

Assessments:

  1. Cardiac MRI (CMR) at 5±2 days post-PCI: MVO, IMH, infarct size (%LVMM), LV/RV ejection fraction, volumes, mass
  2. Targeted next-generation sequencing (NGS) for CHIP mutations (VAF ≥2%): DNMT3A, TET2, ASXL1, and other driver genes
  3. Single-cell RNA sequencing (scRNA-seq) of PBMCs at baseline and 12-month follow-up
  4. Serial blood biomarkers: hsCRP, IL-6, IL-18, NT-proBNP, troponin T, complete blood count
  5. Clinical follow-up visits at 12, 24, and 48 months

Primary Endpoint:

Presence of microvascular obstruction (MVO) and/or intramyocardial hemorrhage (IMH) on CMR at 5±2 days post-PCI in CHIP carriers versus non-carriers.

Secondary Endpoints:

  • Infarct size (% left ventricular myocardial mass, %LVMM)
  • LV and RV ejection fraction, end-diastolic/systolic volumes, myocardial mass
  • MACE: all-cause mortality, non-fatal reinfarction, hospitalization for heart failure at 12, 24, and 48 months
  • Changes in CHIP mutation variant allele frequency (VAF) over time
  • Differential gene expression in immune cell subsets by scRNA-seq
  • Biomarker trajectories (NT-proBNP, hsCRP, IL-6)

Ethics and Regulatory:

The study protocol has been approved by the Research Ethics Committee of the Medical University of Innsbruck and is conducted in accordance with the Declaration of Helsinki and ICH-GCP guidelines. All participants provide written informed consent prior to study inclusion. The study is funded by the KLiF (Klinisch-Interne Forschung) program of the Medical University of Innsbruck.

Studietype

Observationeel

Inschrijving (Geschat)

350

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

  • Naam: Sebastian J Reinstadler, MD, PhD
  • Telefoonnummer: +43 512 504 83772

Studie Locaties

  • Oostenrijk
    • Tyrol
      • Innsbruck, Tyrol, Oostenrijk, 6020
        • Medical University of Innsbruck
        • Contact:
        • Contact:
          • Sebastian J Reinstadler, MD, PhD
          • Telefoonnummer: +43 512 504 83772

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Ja

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

The study population will consist of adult female and male patients aged 18 to 75 years with a first acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention within 12 hours after symptom onset. Patients will be screened at the coronary care unit of the Medical University of Innsbruck. Eligible patients will be invited to participate after primary percutaneous coronary intervention and after assessment of inclusion and exclusion criteria. Standard clinical care and secondary prevention will be performed according to current guideline recommendations.

Beschrijving

Inclusion Criteria:

  • Diagnosis of first acute ST-elevation myocardial infarction according to current European Society of Cardiology guidelines
  • Symptoms consistent with ST-elevation myocardial infarction lasting more than 30 minutes and less than 12 hours before primary percutaneous coronary intervention
  • Treatment with primary percutaneous coronary intervention
  • Age 18 to 75 years
  • Written informed consent

Exclusion Criteria:

  • Prior myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention
  • Persistent hemodynamic instability, Killip class greater than 2 including cardiogenic shock, or resuscitated cardiac arrest not allowing cardiac magnetic resonance imaging
  • Known active or prior malignancy, including hematologic malignancies or myelodysplastic syndromes
  • Prior oncologic treatment with chemotherapy, radiotherapy, or radioisotopes
  • Abnormal baseline complete blood count with clinically significant cytopenia, defined as leukocytes less than 3.0 x 10^9/L, platelets less than 100 x 10^9/L, or hemoglobin less than 10 g/dL
  • Chronic viral infection associated with systemic inflammation
  • Active autoimmune disease or chronic systemic inflammatory disorder
  • Chronic kidney disease with creatinine clearance less than 30 mL/min/1.73 m2
  • Contraindication to cardiac magnetic resonance imaging
  • Pre-ST-elevation myocardial infarction life expectancy of less than 1 year
  • Participation in an interventional trial
  • Limited possibility to attend follow-up examinations, for example residence abroad
  • Pregnancy

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
STEMI Patients
Patients presenting with ST-elevation myocardial infarction (STEMI) who undergo successful primary percutaneous coronary intervention (PCI). All consecutive eligible patients are enrolled regardless of CHIP mutation status. This single cohort is analyzed based on CHIP presence/absence and specific CHIP mutation type (e.g., DNMT3A, TET2, ASXL1).
Diagnostische toets: Clonal hematopoiesis assessment and cardiac magnetic resonance imaging
Participants will undergo blood sampling for assessment of clonal hematopoiesis of indeterminate potential by targeted next-generation sequencing and cardiac magnetic resonance imaging for assessment of myocardial injury, including microvascular obstruction, intramyocardial hemorrhage, infarct size, ventricular function, and myocardial tissue characteristics. Additional biomarker and inflammatory profiling will be performed according to the study protocol.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Occurrence of microvascular injury
Tijdsspanne: 5 ± 2 days after primary percutaneous coronary intervention
Presence of microvascular injury, defined as microvascular obstruction and/or intramyocardial hemorrhage, assessed by cardiac magnetic resonance imaging in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. The outcome will be analyzed according to the presence or absence of clonal hematopoiesis of indeterminate potential.
5 ± 2 days after primary percutaneous coronary intervention

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Infarct size
Tijdsspanne: 5 ± 2 days after primary percutaneous coronary intervention
Infarct size expressed as percentage of left ventricular myocardial mass, assessed by cardiac magnetic resonance imaging in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. The outcome will be analyzed according to the presence or absence of clonal hematopoiesis of indeterminate potential.
5 ± 2 days after primary percutaneous coronary intervention
Left ventricular ejection fraction
Tijdsspanne: 5 ± 2 days, 4 months, and 12 months after primary percutaneous coronary intervention
Left ventricular ejection fraction assessed by cardiac magnetic resonance imaging in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.
5 ± 2 days, 4 months, and 12 months after primary percutaneous coronary intervention
All-cause mortality
Tijdsspanne: Within 12 months after study inclusion.
eath from any cause after study inclusion.
Within 12 months after study inclusion.
Hospitalization for heart failure
Tijdsspanne: Within 12 months after study inclusion.
Hospitalization due to new or worsening heart failure after study inclusion.
Within 12 months after study inclusion.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Medical University Innsbruck

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

20 juni 2026

Primaire voltooiing (Geschat)

20 juni 2029

Studie voltooiing (Geschat)

20 juni 2030

Studieregistratiedata

Eerst ingediend

22 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

22 mei 2026

Eerst geplaatst (Werkelijk)

29 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

29 mei 2026

Laatste update ingediend die voldeed aan QC-criteria

22 mei 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 1195/2024
  • KLP1365525 (Ander subsidie-/financieringsnummer: Austrian Science Fund)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren